Decreased HIF-1 expression in patients with PCOS results in the inhibition of follicle rupture, oocyte release, and corpus luteum formation
GLP1R:Gnas fl/fl [sema] p = 0.0423, WT:Gnas fl/fl [sema] vs
There is currently no FDA-approved indication for tirzepatide specifically for Hashimoto's disease, and no large-scale randomized controlled trials have evaluated tirzepatide as a treatment for this autoimmune thyroid condition
CrossRef The active components of the Danshen-Shanzha herb-pair exert a protective effect on MASLD by synergistically promoting fatty acid oxidation via the activation of PPAR, Plin-5 and Plin-2 Ying Yang, Yaxing Li, Zirong Zhou, Hui Li, Yihan Ma, Wenjie Bi, Mengjiao Li, Xiaoli Liu, Qiang Jia, Liwen Han, Songsong Wang Journal of Ethnopharmacology .2026